AM
Ankit Mahadevia

Ankit Mahadevia insider trades: Spero Therapeutics (SPRO) stock sales

Spero Therapeutics Last trade Aug 28, 2025 24 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
14
Open-market trades
since 2018
1
Company
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ankit reports to the SEC

Open-market buys and sales

14 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 28, 2025SPRO↓ Sell$13K
Feb 5, 2025SPRO↓ Sell$54K
Aug 27, 2024SPRO↓ Sell$8K
Feb 2, 2024SPRO↓ Sell$87K
Aug 28, 2023SPRO↓ Sell$11K
Feb 3, 2023SPRO↓ Sell$22K
Dec 27, 2021SPRO↓ Sell$117K
Nov 4, 2020SPRO↓ Sell$137K
Oct 23, 2020SPRO↓ Sell$285
Oct 14, 2020SPRO↓ Sell$207K
Sep 8, 2020SPRO↓ Sell$11K
Jul 9, 2020SPRO↓ Sell$44K
Jun 25, 2020SPRO↓ Sell$246K
Jul 6, 2018SPRO↓ Sell$82K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other SPRO insiders

Open-market trades in the last 12 months

About Ankit Mahadevia's insider trades

Ankit Mahadevia is an insider at Spero Therapeutics (SPRO). Since Jul 6, 2018, Ankit has reported no open-market purchases and 14 sales worth $1.0M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (10 filings), option exercises (8 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SPRO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.